Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women
Public ClinicalTrials.gov record NCT00755417. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Depomed's Gabapentin Extended Release (G-ER) is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women.
Study identification
- NCT ID
- NCT00755417
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 541 participants
Conditions and interventions
Conditions
Interventions
- Gabapentin Extended-Release (G-ER) 1200 mg Drug
- Gabapentin Extended-Release (G-ER) 1800 mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2008 (Type not available)
- Primary completion
- Aug 2009 (Actual)
- Completion
- Oct 2009 (Actual)
- Last update posted
- Mar 7, 2012
2008 – 2009
United States locations
- U.S. sites
- 45
- U.S. states
- 25
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Montgomery | Alabama | — | — |
| Not listed | Tempe | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Berkely | California | — | — |
| Not listed | La Mesa | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Santa Rosa | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Lakewood | Colorado | — | — |
| Not listed | Waterbury | Connecticut | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Clearwater | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | St. Petersburg | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Sandy Springs | Georgia | — | — |
| Not listed | Savannah | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Madisonville | Kentucky | — | — |
| Not listed | Fall River | Massachusetts | — | — |
| Not listed | Edina | Minnesota | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Billings | Montana | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Moorestown | New Jersey | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Fargo | North Dakota | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | West Reading | Pennsylvania | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Hilton Head Island | South Carolina | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Bellevue | Washington | — | — |
| Not listed | Renton | Washington | — | — |
| Not listed | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00755417, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 7, 2012 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00755417 live on ClinicalTrials.gov.